Knock-down of PQBP1 impairs anxiety-related cognition in mouse

Human Molecular Genetics

Volumn 18, Issue 22, 2009, Pages 4239-4254

  Ito, Hikaru ^a   Yoshimura, Natsue ^a   Kurosawa, Masaru ^b   Ishii, Shunsuke ^c   Nukina, Nobuyuki ^b   Okazawa, Hitoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c RIKEN TSUKUBA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOUBLE STRANDED RNA; GENE PRODUCT; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; POLYGLUTAMINE TRACT BINDING PROTEIN 1; PROTEIN C FOS; PROTEIN P50; SEROTONIN TRANSPORTER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACETYLATION; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MOUSE; GENE EXPRESSION REGULATION; GENE MUTATION; HIPPOCAMPUS; KNOCKOUT MOUSE; MAZE TEST; MEMORY; MEMORY DISORDER; MOUSE STRAIN; NONHUMAN; OPEN FIELD TEST; PATHOGENESIS; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES, TECHNIQUES AND CONCEPTS; SUPPRESSOR GENE; TRANSGENE; UPREGULATION;

ANIMALS; ANXIETY; CARRIER PROTEINS; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEAR PROTEINS;

MUS;

EID: 70350694440     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp378     Document Type: Article

References (71)

1. Chelly, J. and Mandel, J.L. (2001) Monogenic causes of X-linked mental retardation. Nat. Rev. Genet., 2, 669-680.
2. Check, E. (2005) Genetics: The X factor. Nature, 434, 266-267.
3. Carrel, L. and Willard, H.F. (2005) X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434, 400-404.
4. Ropers, H.H. and Hamel, B.C. (2005) X-linked mental retardation. Nat. Rev., 6, 46-57.
5. Kalscheuer, V.M., Freude, K., Musante, L., Jensen, L.R., Yntema, H.G., Gecz, J., Sefiani, A., Hoffmann, K., Moser, B., Haas, S. et al. (2003) Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. Nat. Genet., 35, 313-315.
6. Kleefstra, T., Franken, C.E., Arens, Y.H., Ramakers, G.J., Yntema, H.G., Sistermans, E.A., Hulsmans, C.F., Nillesen, W.N., van Bokhoven, H., de Vries, B.B. et al. (2004) Genotype-phenotype studies in three families with mutations in the polyglutamine-binding protein 1 gene (PQBP1). Clin. Genet., 66, 318-326.
7. Lenski, C., Abidi, F., Meindl, A., Gibson, A., Platzer, M., Frank Kooy, R., Lubs, H.A., Stevenson, R.E., Ramser, J. and Schwartz, C.E. (2004) Novel truncating mutations in the polyglutamine tract binding protein 1 gene (PQBP1) cause Renpenning syndrome and X-linked mental retardation in another family with microcephaly. Am. J. Hum. Genet., 74, 777-780.
8. Stevenson, R.E., Bennett, C.W., Abidi, F., Kleefstra, T., Porteous, M., Simensen, R.J., Lubs, H.A., Hamel, B.C. and Schwartz, C.E. (2005) Renpenning syndrome comes into focus. Am. J. Med. Genet., 134 415-421.
9. de Brouwer, A.D., Yntema, H.G., Kleefstra, T., Lugtenberg, D., Oudakker, A.R., de Vries, B.B., van Bokhoven, H., Van Esch, H., Frints, S.G., Froyen, G. et al. (2007) Mutation frequencies of X-linked mental retardation genes in families from the EuroMRX consortium. Hum. Mutat., 28, 207-208.
10. Waragai, M., Lammers, C.H., Takeuchi, S., Imafuku, I., Udagawa, Y., Kanazawa, I., Kawabata, M., Mouradian, M.M. and Okazawa, H. (1999) PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. Hum. Mol. Genet., 8, 977-987.
11. Okazawa, H., Rich, T., Chang, A., Lin, X., Waragai, M., Kajikawa, M., Enokido, Y., Komuro, A., Kato, S., Shibata, M. et al. (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron, 34, 701-713.
12. Komuro, A., Saeki, M. and Kato, S. (1999) Association of two nuclear proteins, Npw38 and NpwBP, via the interaction between the WW domain and a novel proline-rich motif containing glycine and arginine. J. Biol. Chem., 274, 36513-36519.
13. Nicolaescu, E., Beullens, M., Lesage, B., Keppens, S., Himpens, B. and Bollen, M. (2008) Nature of the nuclear inclusions formed by PQBP1, a protein linked to neurodegenerative polyglutamine diseases. Eur. J. Cell Biol., 87, 817-829.
14. Waragai, M., Junn, E., Kajikawa, M., Takeuchi, S., Kanazawa, I., Shibata, M., Mouradian, M.M. and Okazawa, H. (2000) PQBP-1/Npw38, a nuclear protein binding to the polyglutamine tract, interacts with U5-15kD/dim1p via the carboxyl-terminal domain. Biochem. Biophys. Res. Commun., 273, 592-595.
15. Zhang, Y., Lindblom, T., Chang, A., Sudol, M., Sluder, A.E. and Golemis, E.A. (2000) Evidence that dim1 associates with proteins involved in pre-mRNA splicing, and delineation of residues essential for dim1 interactions with hnRNP F and Npw38/PQBP-1. Gene, 257, 33-43.
16. Makarov, E.M., Makarova, O.V., Urlaub, H., Gentzel, M., Will, C.L., Wilm, M. and Luhrmann, R. (2002) Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298, 2205-2208.
17. Makarova, O.V., Makarov, E.M., Urlaub, H., Will, C.L., Gentzel, M., Wilm, M. and Luhrmann, R. (2004) A subset of human 35S U5 proteins, including Prp19, function prior to catalytic step 1 of splicing. EMBO J., 23, 2381-2391.
18. Okazawa, H., Sudol, M. and Rich, T. (2001) PQBP-1 (Np/PQ): A polyglutamine tract-binding and nuclear inclusion-forming protein. Brain Res. Bull., 56, 273-280.
19. Shinagawa, T. and Ishii, S. (2003) Generation of ski-knockdown mice by expressing a long double-strand RNA from an RNA polymerase II promoter. Genes Dev., 17, 1340-1345.
20. Peier, A.M., Mcllwain, K.L., Kenneson, A., Warren, S.T., Paylor, R. and Nelson, D.L. (2000) Over correction of FMR1 deficiency with YAC transgenics: Behavioral and physical features. Hum. Mol. Genet., 9, 1145-1159.
21. Itoh, J., Nabeshima, T. and Kameyama, T. (1990) Utility of an elevated plus-maze for the evaluation of memory in mice: Effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl) 101, 27-33.
22. Rodgers, R.J., Haller, J., Halasz, J. and Mikics, E. (2003) 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci., 17, 1279-1286.
23. Rodgers, R.J., Johnson, N.J., Cole, J.C., Dewar, C.V., Kidd, G.R. and Kimpson, P.H. (1996) Plus-maze retest profile in mice: Importance of initial stages of trail 1 and response to post-trail cholinergic receptor blockade. Pharmacol. Biochem. Behav., 54, 41-50.
24. Yan, Q.J., Asafo-Adjei, P.K., Arnold, H.M., Brown, R.E. and Bauchwitz, R.P. (2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav., 3, 337-359.
25. Amat, J., Baratta, M.V., Paul, E., Bland, S.T., Watkins, L.R. and Maier, S.F. (2005) Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci., 8, 365-371.
26. Lee, M.D., Somerville, E.M., Kennett, G.A., Dourish, C.T. and Clifton, P.G. (2004) Tonic regulation of satiety by 5-HT receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies? Eur. J. Neurosci., 19, 3017-3025.
27. Warburton, E.C., Koder, T., Cho, K., Massey, P.V., Duguid, G., Barker, G.R., Aggleton, J.P., Bashir, Z.I. and Brown, M.W. (2003) Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. Neuron, 38, 987-996.
28. LaBar, K.S. and Cabeza, R. (2006) Cognitive neuroscience of emotional memory. Nat. Rev. Neurosci., 7, 54-64.
29. Alarcon, J.M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E.R. and Barco, A. (2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron, 42, 947-959.
30. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M. and Tsai, L.H. (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature, 447, 178-182.
31. Korzus, E., Rosenfeld, M.G. and Mayford, M. (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron, 42, 961-972.
32. Levenson, J.M., O'Riordan, K.J., Brown, K.D., Trinh, M.A., Molfese, D.L. and Sweatt, J.D. (2004) Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem., 279, 40545-40559.
33. Shahbazian, M., Young, J., Yuva-Paylor, L., Spencer, C., Antalffy, B., Noebels, J., Armstrong, D., Paylor, R. and Zoghbi, H. (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron, 35, 243-254.
34. Gardian, G., Browne, S.E., Choi, D.K., Klivenyi, P., Gregorio, J., Kubilus, J.K., Ryu, H., Langley, B., Ratan, R.R., Ferrante, R.J. et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 280, 556-563.
35. Kida, S., Josselyn, S.A., Peña de Ortiz, S., Kogan, J.H., Chevere, I., Masushige, S. and Silva, A.J. (2002) CREB required for the stability of new and reactivated fear memories. Nat. Neurosci., 5, 348-355.
36. Kassed, C.A. and Herkenham, M. (2004) NF-kB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety. Behav. Brain Res., 154, 577-584.
37. Liu, A., Hoffman, P.W., Lu, W. and Bai, G. (2004) NF-kappaB site interacts with Sp factors and up-regulates the NR1 promoter during neuronal differentiation. J. Biol. Chem., 279, 17449-17458.
38. Cohen, S. and Greenberg, M.E. (2008) Communication between the Synapse and the Nucleus in neuronal development, plasticity, and disease. Annu. Rev. Cell Dev. Biol., 24, 183-209.
39. Canli, T. and Lesch, K.P. (2007) Long story short: The serotonin transporter in emotion regulation and social cognition. Nat. Neurosci., 10, 1103-1109.
40. Fleischmann, A., Hvalby, O., Jensen, V., Strekalova, T., Zacher, C., Layer, L.E., Kvello, A., Reschke, M., Spanagel, R., Sprengel, R., Wagner, E.F. and Gass, P. (2003) Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J. Neurosci., 23, 9116-9122.
41. Kassed, C.A. and Herkenham, M. (2004) NF-kappaB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety. Behav. Brain Res., 154, 577-584.
42. Boyce-Rustay, J.M. and Holmes, A. (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology, 31, 2405-2414.
43. Tsankova, N., Renthal, W., Kumar, A. and Nestler, E.J. (2007) Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci., 8, 355-367.
44. Ho, A.K., Price, D.M., Dukewich, W.G., Steinberg, N., Arnason, T.G. and Chik, C.L. (2007) Acetylation of histone H3 and adrenergic-regulated gene transcription in rat pinealocytes. Endocrinology, 148, 4592-4600.
45. Sterner, D.E. and Berger, S.L. (2000) Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev., 64 435-459.
46. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev., 12, 599-606.
47. Kornblihtt, A.R., de la Mata, M., Fededa, J.P., Munoz, M.J. and Nogues, G. (2004) Multiple links between transcription and splicing. RNA, 10, 1489-1498.
48. Allemand, E., Batsché, E. and Muchardt, C. (2008) Splicing, transcription, and chromatin: A ménage à trois. Curr. Opin. Genet. Dev., 18, 145-151.
49. Jazayeri, A., McAinsh, A.D. and Jackson, S.P. (2004) Saccharomyces cerevisiae Sin3p facilitates DNA double-strand break repair. Proc. Natl Acad. Sci. USA, 101, 1644-1649.
50. Kao, G.D., McKenna, W.G., Guenther, M.G., Muschel, R.J., Lazar, M.A. and Yen, T.J. (2003) Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Cell Biol., 160, 1017-1027.
51. Sims, R.J. III and Reinberg, D. (2008) Is there a code embedded in proteins that is based on post-translational modifications? Nat. Rev. Mol. Cell Biol., 9, 815-820.
52. Kuhn, A.N., van Santen, M.A., Schwienhorst, A., Urlaub, H. and Lührmann, R. (2009) Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation. RNA, 15, 153-175.
53. Maestri, N.E., Brusilow, S.W., Clissold, D.B. and Bassett, S.S. (1996) Long-term treatment of girls with ornithine, transcarbamylase deficiency. New Eng. J. Med., 335, 855-859.
54. Gardian, G., Browne, S.E., Choi, D.K., Klivenyi, P., Gregorio, J., Kubilus, J.K., Ryu, H., Langley, B., Ratan, R.R., Ferrante, R.J. and Beal, M.F. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 280, 556-563.
55. Kubota, K., Niinuma, Y., Kaneko, M., Okuma, Y., Sugai, M., Omura, T., Uesugi, M., Uehara, T., Hosoi, T. and Nomura, Y. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem., 97, 1259-1268.
56. Johnstone, R.W. and Licht, J.D. (2003) Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell, 4, 13-18.
57. Gilbert, J., Baker, S.D., Bowling, M.K., Grochow, L., Figg, W.D., Zabelina, Y., Donehower, R.C. and Carducci, M.A. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292-2300.
58. Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N.W., Ratan, R.R., Luthi-Carter, R. and Hersch, S.M. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 9418-9427.
59. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 2041-2046.
60. Minamiyama, M., Katsuno, M., Adachi, H., Waza, M., Sang, C., Kobayashi, Y., Tanaka, F., Doyu, M., Inukai, A. and Sobue, G. (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet., 13, 1183-1192.
61. Gardian, G., Browne, S.E., Choi, D.-K., Klivenyi, P., Gregono, J., Kubilus, J.K., Ryu, H., Langley, B., Raton, R.R., Ferrante, R.J. and Beal, M.F. (2005) Neuroprotective effect of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem., 280, 556-563.
62. Ying, M., Xu, R., Wu, X., Zhu, H., Zhuang, Y., Han, M. and Xu, T. (2006) Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J. Biol. Chem., 281, 12580-12586.
63. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M. et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 413, 739-743.
64. Gardian, G., Yang, L., Cleren, C., Calingasan, N.Y., Klivenyi, P. and Beal, M.F. (2004) Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med., 5, 235-241.
65. Ryu, H., Smith, K., Camelo, S.I., Carreras, I., Lee, J., Iglesias, A.H., Dangond, F., Cormier, K.A., Cudkowicz, M.E., Brown, R.H. Jr and Ferrante, R.J. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem., 93, 1087-1098.
66. Green, K.N., Steffan, J.S., Martinez-Coria, H., Sun, X., Schreiber, S.S., Thompson, L.M. and LaFerla, F.M. (2008) Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci., 28, 11500-11510.
67. Zhao, K., Harshaw, R., Chai, X. and Marmorstein, R. Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD+-dependent Sir2 histone/protein deacetylases. Proc. Natl Acad. Sci. USA, 101 8563-8568.
68. Sanders, B.D., Zhao, K., Slama, J.T. and Marmorstein, R. (2007) Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes. Mol. Cell, 25, 463-472.
69. Almeida, A.M., Murakami, Y., Baker, A., Maeda, Y., Roberts, I.A., Kinoshita, T., Layton, D.M. and Karadimitris, A. (2007) Targeted therapy for inherited GPI deficiency. New Engl. J. Med., 356, 1641-1647.
70. Huang, Y. and Carmichael, G.G. (1996) Role of polyadenylation in nucleocytoplasmic transport of mRNA. Mol. Cell. Biol., 16, 1534-1542.
71. Yonaha, M. and Proudfoot, N.J. (1999) Specific transcriptional pausing activates polyadenylation in a coupled in vitro system. Mol. Cell, 3, 593-600.